Table 1.
Clinical studies with immunotherapy for patients with Please define this term if appropriate.
| Number of Study | Immune Target | Agent/Compound | Phase of Study |
|---|---|---|---|
| NCT01876511 | PD-1 | Pembrolizumab | II |
| NCT02981524 | PD-1 | Cyclophosphamide followed by Pembrolizumab | II |
| NCT03657641 | PD-1 | Pembrolizumab + Vicriviroc | I/II |
| NCT03631407 | PD-1 | Pembrolizumab + Regorafenib | II |
| NCT03475004 | PD-1 | Pembrolizumab, Bevacizumab, and Binimetinib | II |
| NCT03658772 | PD-1 | Pembrolizumab + grapiprant | I |
| NCT03519412 | PD-1 | Pembrolizumab + temozolomide | II |
| NCT02713373 | PD-1 | Pembrolizumab + cetuximab | I/II |
| NCT02375672 | PD-1 | Pembrolizumab + FOLFOX | II |
| NCT03332498 | PD-1 | Pembrolizumab + Ibrutinib | I/II |
| NCT02851004 | PD-1 | Pembrolizumab + SBRT | I/II |
| NCT02837263 | PD-1 | Pembrolizumab + BBI609 | I |
| NCT02992912 | PD-1 | Atezolizumab + stereotactic ablative radiotherapy | II |
| NCT03712943 | PD-1 | Nivolumab + Regorafenib | I |
| NCT03711058 | PD-1 | Nivolumab + Copanlisib | I/II |
| NCT03414983 | PD-1 | Nivolumab, Oxaliplatin, Leucovorin, Fluorouracil, Bevacizumab | II/III |
| NCT02860546 | PD-1 | Nivolumab + TAS-102 | II |
| NCT03026140 | PD-1 and CTLA-4 | Nivolumab + Ipilimumab +/− celecoxib | I/III |
| NCT03693846 | PD-1 and CTLA-4 | Nivolumab + Ipilimumab | II |
| NCT03104439 | PD-1 and CTLA-4 | Nivolumab + Ipilimumab + radiotherapy | II |
| NCT03377361 | PD-1 and CTLA-4 | Nivolumab + Ipilimumab + Trametinib | I/II |
| NCT03832621 | PD-1 and CTLA-4 | Nivolumab, Ipilimumab, Temozolomide | II |
| NCT02327078 | PD-1 and IDO | Nivolumab + Epacadostat | VII |
| NCT02983578 | PD-L1 | AZD9150 + MEDI4736 | II |
| NCT02982694 | PD-L1 | Atezolizumab + Bevacizumab | II |
| NCT02777710 | PD-L1 | Durvalumab + Pexidartinib | I |
| NCT03827044 | PD-L1 | Avelumab | III |
| NCT02669914 | PD-L1 | Durvalumab | II |
| NCT02754856 | PD-L1 and CTLA-4 | MEDI4736 + Tremelimumab | I |
| NCT03202758 | PD-L1 and CTLA-4 | Durvalumab, Tremelimumab, and FOLFOX | I/II |
NCT, national clinical trial; PD-1, programmed cell death-1; PD-1, programmed cell death-1 ligand; CTLA-4, cytotoxic T-lymphocyte-associated protein 4; IDO, indoleamine-pyrrole 2,3-dioxygenase.